Conv. Plasma
Nigella Sativa
Peg.. Lambda

All HCQ studies
Meta analysis
Home COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 27% Improvement Relative Risk HCQ  Fernández-Cruz et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 71 patients in Spain (March - May 2020) Lower mortality with HCQ (not stat. sig., p=0.47) Fernández-Cruz et al., Clinical Infect.., Jan 2022 Favors HCQ Favors control

Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: An age-matched cohorts study

Fernández-Cruz et al., Clinical Infection in Practice, doi:10.1016/j.clinpr.2022.100137
Jan 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 71 hospitalized haematologic patients in Spain, showing lower mortality with HCQ treatment in unadjusted results and without statistical significance.
Although the 27% lower mortality is not statistically significant, it is consistent with the significant 24% lower mortality [19‑28%] from meta analysis of the 244 mortality results to date. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 27.0% lower, RR 0.73, p = 0.47, treatment 23 of 63 (36.5%), control 4 of 8 (50.0%), NNT 7.4.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fernández-Cruz et al., 31 Jan 2022, retrospective, Spain, peer-reviewed, 10 authors, study period March 2020 - May 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Clinical Infection in Practice 13 (2022) 100137 Contents lists available at ScienceDirect Clinical Infection in Practice journal homepage: Case Reports and Series Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: An age-matched cohorts study☆ Ana Fernández-Cruz a, g, *, Alba Puyuelo b, Lucía Núñez Martín-Buitrago b, Enrique SánchezChica c, Carmen Díaz-Pedroche d, h, j, Rosa Ayala e, h, Manuel Lizasoain f, h, Rafael Duarte b, g, i, Carlos Lumbreras f, h, j, Juan Antonio Vargas c, g, i a Infectious Diseases Department, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain Haematology Department, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain c Internal Medicine Department, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain d Internal Medicine Department, Hospital Doce de Octubre, Madrid, Spain e Haematology Department, Hospital Doce de Octubre, Madrid, Spain f Infectious Diseases Department, Hospital Doce de Octubre, Madrid, Spain g Fundación de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Spain h Fundación para la Investigación Biomédica del Hospital Universitario, 12 de Octubre, Spain i Universidad Autónoma de Madrid, Spain j Universidad Complutense de Madrid, Spain b A R T I C L E I N F O A B S T R A C T Keywords COVID-19 Haematologic Outcome Mortality Background and Objectives: The characteristics of COVID-19 in haematologic patients compared to nonhaematologic patients have seldom been analyzed. Our aim was to analyze whether there are differences in clinical characteristics and outcome of haematologic patients with COVID-19 as compared to non-haematologic. Patients and methods: Retrospective cohort study in 2 University hospitals of patients admitted with laboratoryconfirmed COVID-19 included in the SEMICOVID19 database. The cohort with underlying haematologic disease was compared to a cohort of age and date-of-COVID-19-matched controls without haematologic disease (1:2). Results: 71 cases and 142 controls were included from March-May 2020. Twenty (28.1%) had received recent chemotherapy. Twelve (16.9%) were stem cell transplant recipients (SCT). Eleven (15.5%) were neutropenic concurrently with COVID-19 diagnosis. Haematologic patients presented ARDS (58.5 vs 20.7%, p = 0.0001), thrombotic complications (15.7 vs 2.1%, p = 0.002), DIC (5.7 vs 0.0%, p = 0.011), heart failure (14.3 vs 4.9%, p = 0.029) and required ICU admission (15.5 vs 2.8%, p = 0.001), MV (14.1% vs 2.1%, p 0.001), steroid (64.8 vs 33.1%, p = 0.0001), tocilizumab (33.8 vs 8.5%, p = 0.0001) or anakinra treatment (9.9% vs 0%, p = 0.0001) more often. In-hospital mortality was significantly higher (38.0% vs 18.3%, p = 0.002). Conclusions: Our results suggest COVID-19 has worse outcomes in haematologic patients than in nonhaematologic, independently of age, and that the development of ARDS and thrombotic complications drive the higher in-hospital mortality. Abbreviations: ARDS, acute respiratory distress syndrome; C-RP, C-reactive protein; CI, confidence interval; CLL, chronic lymphocytic leukemia; COVID-19, Coronavirus disease 2019; DIC, disseminated intravascular coagulation; ECOG scale, Eastern Cooperative Oncology Group scale; G-CSF, granulocyte stimulating factor; HFNC, high flow nasal cannula; ICU, Intensive Care Unit; IL6, Interleukin 6; IQR,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop